# DESCRIPTION

- claim priority to provisional patent application

## FIELD OF THE INVENTION

- define field of invention as biomarkers in DNA repair mechanisms

## BACKGROUND OF THE INVENTION

- discuss limitations of current cancer treatment
- motivate DNA repair gene alterations as tool for cancer treatment
- highlight unexplored area of de novo pyrimidine synthesis pathway

## SUMMARY OF THE INVENTION

- introduce method of predicting survival rate of cancer patient
- determine expression levels of genes in de novo pyrimidine synthesis pathway
- optionally determine expression levels of genes in nucleotide excision repair pathway
- predict survival rate based on expression levels
- introduce method of predicting patient's responsiveness to chemotherapy
- determine expression levels of genes in de novo pyrimidine synthesis pathway
- optionally determine expression levels of genes in nucleotide excision repair pathway
- predict patient's responsiveness to chemotherapy based on expression levels
- introduce method of providing treatment regimen for cancer patient
- determine expression levels of genes in de novo pyrimidine synthesis pathway
- optionally determine expression levels of genes in nucleotide excision repair pathway
- provide treatment regimen based on expression levels

## DETAILED DESCRIPTION

- motivate de novo pyrimidine synthesis pathway
- introduce nucleotide excision repair pathway
- describe prognostic analysis of de novo pyrimidine synthesis and nucleotide excision repair pathways
- define terms used in the invention
- describe obtaining omics data for tumor cells
- describe methods of obtaining omics data
- define omics data
- describe computational analysis of sequence data
- describe analysis of tumor and matched normal tissue
- describe transcriptomic analysis
- describe proteomic analysis
- describe gene expressions and implications in survival rate and resistance to chemotherapy
- describe de novo pyrimidine synthesis genes related to overall survival rate
- analyze nucleotide excision repair genes co-altered with CAD
- describe prognostic significance of CAD and NER genes
- describe Kaplan-Meier plots and boxplots
- describe OncoPrint visualization and heat map
- summarize results of co-alteration analysis and prognostic significance
- introduce multifactorial analysis of CAD/POLD2 expression
- derive regression coefficients for CoxPH validation model
- generate Kaplan-Meier plots for patient OS
- conduct multivariate Cox regression analysis
- examine CAD and POLD2 association with drug response
- determine differential gene expression significance
- calculate Pearson correlation coefficients
- contemplate CAD and POLD2 roles in pyrimidine synthesis and nucleotide excision repair
- associate CAD and POLD2 expression with survival rate and chemotherapy response
- determine omics data for tumor cell
- measure mRNA quantities using real-time RT-PCR
- normalize mRNA quantities against reference genes
- contemplate inverse relationship between CAD/POLD2 expression and survival rate
- determine treatment regimen based on CAD/POLD2 expression levels
- recommend cisplatin-based chemotherapy based on predicted resistance
- contemplate additional omics information for corroborating survival rate prediction
- identify mutation information of CAD and/or POLD2
- associate mutation information with predicted survival rate
- contemplate treatment method for a mammal or patient having a tumor
- obtain omics data for tumor cell
- determine expression levels of de novo pyrimidine synthesis pathway gene and/or nucleotide excision repair pathway gene
- treat patient with chemotherapy based on expression levels
- contemplate predetermined threshold for de novo pyrimidine synthesis pathway gene and/or nucleotide excision repair pathway gene
- administer cisplatin-based chemotherapy in a dose and schedule effective to treat the tumor
- determine effectiveness of cisplatin-based chemotherapy based on CAD and/or POLD2 expression levels

